Pharmaceutical News

RSS

The potential of Sofosbuvir against COVID-19 neurological symptoms

Researchers discuss how SARS-CoV-2 infects cortical neurons and damages their synapses that form the connection between brain cells.

25 Nov 2022

Study aims to develop broad-spectrum antivirals against SARS-CoV-2 via drug repurposing strategies

This study aims to determine which FDA-approved compound(s) can be repurposed as a broad-spectrum antiviral drug(s) against SARS-CoV-2 and variants.

24 Nov 2022

Young people treated for sleep disorders with benzodiazepines may be at higher risk of overdose

Teens and young adults who are treated for sleep disorders with benzodiazepines such as Xanax – a medication commonly prescribed to treat anxiety and insomnia – may be at a higher risk of overdose, according to Rutgers researchers.

23 Nov 2022

Novel mRNA vaccines encoding Monkeypox virus proteins show promise in preclinical studies

In a recent study posted to the bioRxiv* preprint server, researchers in China demonstrated the efficacy of three messenger ribonucleic acid (mRNA) technology-based Monkeypox virus (MPXV) vaccines in combating a lethal Vaccinia virus (VACV) challenge in mice models.

22 Nov 2022

Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant

A novel mAb against the SARS-CoV-2 RBD through a hybridoma technique, followed by chimerization and expression in plants.

22 Nov 2022

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

21 Nov 2022

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2

21 Nov 2022

Comprehensive analysis outlines the potential toxicities of antibody drug conjugates

Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients.

21 Nov 2022

Anti-inflammatory pain relievers may worsen inflammation in osteoarthritis

Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen inflammation in the knee joint over time, according to a new study being presented next week at the annual meeting of the Radiological Society of North America.

21 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Jynneos vaccine for Monkeypox not linked to hospitalization, serious cardiac events

In a recent study posted to the medRxiv* preprint server, researchers investigated the incidence of cardiac AESIs (adverse events of special interest) among Kaiser Permanente Northwest (KPNW) members who had received JYNNEOS vaccinations against the monkeypox (MPX) virus.

16 Nov 2022

ADHD drug associated with lowest risk of amphetamine-related hospitalizations and death

The ADHD medication lisdexamfetamine was associated with the lowest risk of hospitalization and death in people with amphetamine addiction, when medications generally used among persons with substance use disorders were compared.

16 Nov 2022

Amyloid-PET scanning has misled the FDA into granting approval for Aduhelm

Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer's disease.

16 Nov 2022

COVID-19 mRNA boosters induce robust but non-durable immune response in the elderly

A study published in the journal Frontiers in Immunology describes that the third booster dose of coronavirus disease 2019 (COVID-19) effectively induces an immune response against immunologically more fit variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the immunity induced by the booster vaccination is transient and gradually declines over time.

15 Nov 2022

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

In a recent study published in the journal npj Vaccines, researchers in China designed, produced, and evaluated the neutralization efficacy of a recombinant coronavirus disease 2019 (COVID-19) vaccine containing four hot-spot substitution mutations based on a prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) trimer.

15 Nov 2022

Medicare plan finder likely won’t note new $35 cap on out-of-pocket insulin costs

A big cut in prescription drug prices for some Medicare beneficiaries kicks in next year, but finding those savings isn't easy.

15 Nov 2022

Moderna's bivalent boosters trigger strong antibody response against latest subvariants

Moderna reports the efficacy of a bivalent COVID-19 vaccine booster dose.

14 Nov 2022

A novel mRNA-based vaccine candidate against the rabies virus

Scientists have developed a novel mRNA-based vaccine candidate against the rabies virus. The vaccine induces a strong antibody response and exhibits high protective efficacy against lethal rabies infection in mice and dogs. A full report about the vaccine has been published in the Virology Journal.

14 Nov 2022

New fentanyl vaccine could prevent deadly opioid from entering the brain

A research team led by the University of Houston has developed a vaccine targeting the dangerous synthetic opioid fentanyl that could block its ability to enter the brain, thus eliminating the drug's "high."

14 Nov 2022

More adverse reactions following bivalent COVID-19 mRNA booster vaccine

A recent study posted to medRxiv* examined adverse reactions after administration of a bivalent BNT162b2 coronavirus disease 2019 (COVID-19) vaccine booster.

13 Nov 2022

Previous
1
...
90
91
92
93
94
95
96
...
1460
Next

Pharmaceutical News

The potential of Sofosbuvir against COVID-19 neurological symptoms

Study aims to develop broad-spectrum antivirals against SARS-CoV-2 via drug repurposing strategies

Young people treated for sleep disorders with benzodiazepines may be at higher risk of overdose

Novel mRNA vaccines encoding Monkeypox virus proteins show promise in preclinical studies

Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

Comprehensive analysis outlines the potential toxicities of antibody drug conjugates

Anti-inflammatory pain relievers may worsen inflammation in osteoarthritis

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

Jynneos vaccine for Monkeypox not linked to hospitalization, serious cardiac events

ADHD drug associated with lowest risk of amphetamine-related hospitalizations and death

Amyloid-PET scanning has misled the FDA into granting approval for Aduhelm

COVID-19 mRNA boosters induce robust but non-durable immune response in the elderly

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

Medicare plan finder likely won’t note new $35 cap on out-of-pocket insulin costs

Moderna's bivalent boosters trigger strong antibody response against latest subvariants

A novel mRNA-based vaccine candidate against the rabies virus

New fentanyl vaccine could prevent deadly opioid from entering the brain

More adverse reactions following bivalent COVID-19 mRNA booster vaccine

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News